MD Anderson Now Owns the Latest in Precision Radiation Treatment
One of the leading centers for cancer care worldwide has annouced it has purchased a pair of Elekta Versa HD linear accelerators and will be treating patients with them by January of 2014.
The University of Texas MD Anderson Cancer Center is the proud owner of two such accelerators. Each is a 510(k) FDA-cleared radiation therapy system capable of performing both high-volume conventional techniques and the most advanced linear-accelerator treatments that require the greatest targeting precision.
The system, Versa HD, comes equipped with the Agility multileaf collimator for high-speed, high-precision beam shaping, which allows for very precise and accurate tumor targeting while preserving healthy tissue. This is also an upgrade over prior beam-shaping tech because the Versa HD can deliver radiation to a significantly larger treatment field than anything before it, which will allow radiology oncologists to treat a broader spectrum of tumors and cancers.
"To have MD Anderson employ our latest technology gives us added confidence that Elekta is providing the tools that top healthcare providers need to treat their patients," said Jay Hoey, executive vice president of Elekta North America.
Source: MD Anderson
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
